Previous studies have suggested that desmopressin may reduce the bleeding diathesis that often complicates open-heart surgery. To pursue this question further, we performed a double-blind, randomized, placebo-controlled trial to determine whether the previously reported beneficial effect of desmopressin on hemostasis during complex cardiac surgery was applicable to all elective cardiac surgical procedures involving cardiopulmonary bypass. In 150 consecutive patients, most of whom underwent primary coronary-artery bypass grafting, we compared the effects of intravenous desmopressin (0.3 microgram per kilogram of body weight) with those of saline placebo on postoperative blood loss and the need to replace blood products. The median amount of blood lost within the first 24 hours after operation was similar in the desmopressin and placebo groups (865 vs. 738 ml; P = 0.26). The postoperative use of blood replacement products did not differ significantly between the groups (1025 ml [95 percent confidence interval, 300 to 4140 ml] in the desmopressin group and 860 ml [247 to 5346 ml] in the placebo group). Desmopressin is believed to exert its hemostatic effect by releasing von Willebrand factor. The level of ristocetin cofactor, a functional index of the level of von Willebrand factor, was increased approximately twofold from base line in both treatment groups 90 minutes and 24 hours after the administration of medication. Similarly, the levels of von Willebrand factor multimers increased uniformly in both groups. These findings may be consistent with a normal stress response of von Willebrand factor to major surgery and could explain our failure to detect a therapeutic effect of desmopressin. We conclude that the majority of patients who undergo elective cardiac surgery receive no hemostatic benefit from the use of desmopressin.
Source Information
Department of Anesthesia, Vancouver General Hospital, University of British Columbia, Canada.
This article has been cited by other articles:
Mannucci, P. M., Levi, M.
(2007). Prevention and Treatment of Major Blood Loss. NEJM
356: 2301-2311
[Full Text]
Levy, J. H.
(2005). Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. Am J Health Syst Pharm
62: S15-S19
[Abstract][Full Text]
Ozal, E., Kuralay, E., Bingol, H., Cingoz, F., Ceylan, S., Tatar, H.
(2002). Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis?. J. Thorac. Cardiovasc. Surg.
123: 539-543
[Abstract][Full Text]
Oliver, W. C. Jr, Santrach, P. J., Danielson, G. K., Nuttall, G. A., Schroeder, D. R., Ereth, M. H.
(2000). Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations. Ann. Thorac. Surg.
70: 1923-1930
[Abstract][Full Text]
Despotis, G. J., Goodnough, L. T.
(2000). Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann. Thorac. Surg.
70: S20-32
[Abstract][Full Text]
Savarese, D., Waitkus, H., Stewart, F. M., Callery, M.
(1999). Bloodless Medicine and Surgery. J Intensive Care Med
14: 20-33
Mannucci, P. M.
(1998). Hemostatic Drugs. NEJM
339: 245-253
[Full Text]
Mannucci, P. M.
(1997). Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. Blood
90: 2515-2521
[Full Text]
Despotis, G. J., Joist, J. H., Goodnough, L. T.
(1997). Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. Clin. Chem.
43: 1684-1696
[Abstract][Full Text]
Levy, J. H., Pifarre, R., Schaff, H. V., Horrow, J. C., Albus, R., Spiess, B., Rosengart, T. K., Murray, J., Clark, R. E., Smith, P., Nadel, A., Bonney, S. L., Kleinfield, R.
(1995). A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting. Circulation
92: 2236-2244
[Abstract][Full Text]
Casas, J. I., Zuazu-Jausoro, I., Mateo, J., Oliver, A., Litvan, H., Muniz-Diaz, E., Aris, A., Caralps, J. M., Fontcuberta, J.
(1995). APROTININ VERSUS DESMOPRESSIN FOR PATIENTS UNDERGOING OPERATIONS WITH CARDIOPULMONARY BYPASS: A double-blind placebo-controlled study. J. Thorac. Cardiovasc. Surg.
110: 1107-1117
[Abstract][Full Text]
Walenga, J. M., Fareed, J., Bick, R. L., Pifarre, R.
(1995). New Anticoagulants for the Cardiovascular Patient. CLIN APPL THROMB HEMOST
1: 24-30
[Abstract]
Weisel, R. D
(1993). Agents that modify haemostasis after cardiopulmonary bypass. Perfusion
8: 6-12
[Abstract]
Prentice, C., Orchard, M., Goodchild, C.
(1993). Haemostatic dysfunction and cardiopulmonary bypass: mechanisms and therapeutic choices. Perfusion
8: 28-35
[Abstract]
Spence, R. K.
(1993). Transfusion Practices in Vascular Surgery. PERSPECT VASC SURG ENDOVASC THER
6: 14-43
Previous
